Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Nirav N. Shah, Zulfa Omer, Graham P. Collins, Francesco Forconi, Alexey Danilov, John C. Byrd, Dima El-Sharkawi, Emma Searle, Alvaro J Alencar, Shuo Ma, Sarah Injac, Talha Munir

Blood (2024) 144 (Supplement 1): 884.

https://doi.org/10.1182/blood-2024-194839

Published: 2024

Journal Articles

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Samar Kulkarni, Adrian Bloor, Mike Dennis, Anna Z Castleton, Mark Williams, Ahmed Abdulgawad, Tim Somervaille, Daniel H Wiseman, Vismay Deshani, Emma Searle, Angie Leather, John Murray, Sally Pickering, James Cavet

Blood (2024) 144 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2024-211021

Published: 2024

Journal Articles

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Vismay Deshani, H Hemat, Adrian Bloor, Mike Dennis, Alex Peel, Adam Jeans, Anna Z Castleton, Emma Searle, Daniel H Wiseman, Mark Williams, Richard Chasty, Ahmed Abdulgawad, Tim Somervaille, John Murray, Jane Robertson, James Cavet, Samar Kulkarni

Blood (2024) 144 (Supplement 1): 7897.

https://doi.org/10.1182/blood-2024-198526

Published: 2024

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Blood (2024) 144 (Supplement 1): 495.

https://doi.org/10.1182/blood-2024-200181

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

Phase 1/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy

Anthony S. Stein, Emma Searle, Sylvain Garciaz, Uma Borate, Kyle Jensen, Asma Kefsi, Marie Bernardo, Yue Yang, Sarah Cooley, Ashish Bajel

Blood (2024) 144 (Supplement 1): 2883.3.

https://doi.org/10.1182/blood-2024-205923

Published: 2024

Journal Articles

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, Paula Maguire, Jiwon Yang, James G Keck, Laura Maher, Mark Graham, Martin F Kaiser, Emma Searle, Mark Sumeray

Blood (2024) 144 (Supplement 1): 2061.

https://doi.org/10.1182/blood-2024-204734

Published: 2024

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Blood (2024) 144 (Supplement 1): 594.

https://doi.org/10.1182/blood-2024-200300

Published: 2024

Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Geoff Fisher, Sue Brook, Hendrik-Tobias Arkenau, Ayan Aden Yusuf, Peter Tan

Blood (2024) 144 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2024-210105

Published: 2024

Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2024-206912

Published: 2024

Journal Articles

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Emma Searle, Victoria Campbell, Charlotte Pawlyn, Ceri Bygrave, Sarah Gooding, James Cavet, Matthew W. Jenner, Vivek Radhakrishnan, Steve Knapper, Dima el-Sharkawi, Jenny O'Nions, Tomasz Knurowski, Karen Clegg, Will Henry West, Debbie Haynes, Kris Frese, Tim Somervaille

Blood (2024) 144 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2024-199779

Published: 2024

Journal Articles

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2023-174652

Published: 2023

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Polb 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

Emma Searle, Liam Tremble, Rakesh Popat, Digna de Bruin, Matthijs Moerland, Brendan Buckley

Blood (2023) 142 (Supplement 1): 2093.

https://doi.org/10.1182/blood-2023-189062

Published: 2023

Journal Articles

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Emma Searle, Francesco Forconi, Kim Linton, Alexey Danilov, Pam McKay, David Lewis, Dima El-Sharkawi, Mary Gleeson, John Riches, Sarah G. Injac, Ted Shih, Srinand Nandakumar, May Tan, Ganesh Cherala, Erin Meredith, Graham P. Collins

Blood (2023) 142 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2023-179508

Published: 2023

Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Hendrik-Tobias Arkenau, Sue Brook, Charlotte Burmester, Geoff Fisher, Katie Stoddart, Peter Tan

Blood (2023) 142 (Supplement 1): 4285.

https://doi.org/10.1182/blood-2023-188606

Published: 2023

NARROW

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Polb 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only